Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy

American Journal of Ophthalmology

Volumn 134, Issue 3, 2002, Pages 376-382

  Simó, Rafael ^a   Lecube, Albert ^a   Segura, Rosa M ^a   García Arumí, José ^a   Hernández, Cristina ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VITRECTOMY; VITREOUS BODY;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOKINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITRECTOMY; VITREOUS BODY;

EID: 0036742892     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01538-6     Document Type: Article

References (49)

1. Aiello L.P., Gardner T.W., King G.L., et al. Diabetic retinopathy. (Technical Review) Diabetes Care. 21:1998;143-156.
2. Aiello L.P., Avery R.L., Arrig P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331:1994;1480-1487.
3. Miller J., Adamis A.P., Shima D.T., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 145:1994;574-584.
4. Pierce E.A., Avery R.L., Foley E.D., Aiello L.P., Smith L.E.H. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 92:1995;905-909.
5. Aiello L.P., Pierce E.A., Foley D.E., et al. Suppression of retinal vascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 92:1995;10457-10461.
6. Adamis A.P., Shima D.T., Tolentino M., et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch Ophthalmol. 114:1996;66-71.
7. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1996;1820-1828.
8. Suzuma I., Hata Y., Clermont A., et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2. Potential Mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes. 50:2001;444-454.
9. Hofman P., van Blijswijk B.C., Gaillard P.J., Vrensen G.F., Schlingemann R.O. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch Ophthalmol. 119:2001;861-866.
10. Kohner E.M., Hamilton A.M., Joplin G.F., Fraser T.R. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes. 25:1976;1054-1060.
11. Merimee T.J. Metabolic and clinical studies in growth hormone deficient dwarfs: a ten-year follow-up. N Engl J Med. 298:1978;1217-1222.
12. Hyer S.L., Sharp P.S., Brooks R.A., Burrin J.M., Kohner E.M. Progression of diabetic retinopathy and changes in serum insulin-like growth factor-1 (IGF-1) during continuous subcutaneous insulin infusion. Horm Metab Res. 21:1989;18-22.
13. Hyer S.L., Sharp P.S., Brooks R.A., Burrin J.M., Kohner E.M. A two-year follow-up study of serum insulin-like growth factor-1 in diabetics with retinopathy. Metabolism. 38:1989;586-589.
14. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol. 82:1998;725-730.
15. Knott R. Insulin-like growth factor type 1 - friend or foe? Br J Ophthalmol. 82:1998;719-721.
16. Wang Q., Dills D.G., Klein R., Klein B.E.K., Moss S.E. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy ? Diabetes. 44:1995;161-164.
17. Jansen J.A.M.J.L., Lamberts S.W.J. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxford). 52:2000;1-9.
18. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 271:1996;29483-29488.
19. Akagi Y., Liu W., Zebrowski B., Xie K., Ellis L.M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 58:1998;4008-4014.
20. Goad D.L., Rubin J., Wang H., Tashjian A.H., Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and mutine osteoblasts induced by insulin-like growth factor I. Endocrinology. 137:1996;2262-2268.
21. Wang D.S., Yamazaki K., Nohtomi K., et al. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res. 11:1996;472-479.
22. Bermont L., Lamielle F., Fauconnet S., Esumi H., Weiz A., Adessi G.L. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int J Cancer. 85:2000;117-123.
23. Punglia R.S., Lu M., Hsu J., et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 46:1997;1619-1626.
24. Kaven C.W., Spraul C.W., Zavazava N.K., Lang G.K., Lang G.E. Growth factor combinations modulate human retinal pigment epithelial cell proliferation. Curr Eye Res. 20:2000;480-487.
25. Smith L.E.H., Kopchick J.J., Chen W., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 276:1997;1706-1709.
26. Smith L.E.H., Shen W., Perruzzi C., et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nature Med. 5:1999;1390-1395.
27. Hellstrom A., Perruzzi C., Ju M., et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci (USA). 98:2001;5804-5808.
28. Grant M., Fitzgerald C., Merimee T.J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes. 35:1986;416-420.
29. Meyer-Schwickerath R., Pfeiffer A., Blum W.F., et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 92:1993;2620-2625.
30. Boulton M., Gregor Z., McLeod D., et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 81:1997;228-233.
31. Burgos R., Mateo C., Cantón R., Hernández C., Mesa J., Simó R. Vitreous levels of IGF-1, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy. A case-control study. Diabetes Care. 23:2000;80-83.
32. Ozaki H., Hayashi H., Oshima K. Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res. 28:1996;356-360.
33. Burgos R., Simó R., Audí L., et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentration in diabetic retinopathy. Diabetologia. 40:1997;1107-1109.
34. Hernández C., Burgos R., Canton A., García-Arumí J., Segura R.M., Simó R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 24:2001;516-521.
35. Spranger J., Bühnen J., Jansen V., et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy. Horm Metab Res. 32:2000;196-200.
36. Ambati J., Chalam K.V., Chawla D.K., et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 115:1997;1161-1166.
37. Harboe M. A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest. 11:1959;66-70.
38. Fairbanks V.F., Ziesmer S.C., O'Brien P.C. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem. 38:1992;132-140.
39. Nagai Y., Ando H., Nohara E., Yamashita H., Takamura T., Kobayashi K. Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm Metab Res. 32:2000;326-329.
40. Gerhardinger C., McClure K.D., Romeo G., Podesta F., Lorenzi M. IGF-I mRNA and signaling in the diabetic retina. Diabetes. 50:2001;175-183.
41. Lowe W.L., Florkiewicz R.Z., Yorek M.A., Spanheimer R.G., Albrecht B.N. Regulation of growth factor mRNA levels in the eyes of diabetic rats. Metabolism. 44:1995;1038-1045.
42. Averbukh E., Weiss O., Halpert M., et al. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hipoxic conditions. Metabolism. 47:1998;1331-1336.
43. Spoerri P.E., Ellis E.A., Tarnuzzer R.W., Grant M.B. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth Horm IGF Res. 8:1998;125-132.
44. Vaughan-Thomas A., Gilbert S.J., Duance V.C. Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci. 41:2000;3299-3304.
45. Lars-Olof H., Allers A., Gümbel H., Scharrer I., Koch F. Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic retinopathy. Retina. 19:1999;383-389.
46. Clemmons D.R. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev. 22:2001;800-817.
47. Mohseni-Zadeh S., Binoux M. Insulin-like growth factor (IGF) binding protein -3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology. 138:1997;5645-5648.
48. Lalou C., Lassarre C., Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology. 137:1996;3206-3212.
49. Maile L.A., Gill Z.P., Perks C.M., Holly J.M. The role of cell surface attachment and proteolysis in insulin-like growth factor (IGF) independent effects of insulin-like growth factor binding protein-3 on epithelial cells. Endocrinology. 140:1999;4040-4045.